BioCentury | Sep 30, 2020
Product Development

Ovid looks to broad path forward for rare epilepsy program

Three years after striking a deal with Takeda to take the lead on developing the Japanese pharma’s soticlestat, Ovid is considering multiple paths to market for the therapy in rare epileptic encephalopathies.  On Wednesday, Ovid...
BioCentury | Aug 26, 2020
Product Development

Sizing up Ovid’s soticlestat among Dravet therapies

Ovid and Takeda are zeroing in on Dravet syndrome patients for a Phase III trial of soticlestat after Phase II data showed the therapy fared better in the smaller indication than it did in Lennox-Gastaut syndrome....
BioCentury | May 28, 2020
Management Tracks

Quick departure for Semerjian as Immunomedics CEO; plus Ziopharm, Kinnate, Applied Therapeutics, Relmada, AskBio and more

Less than two months after becoming president and CEO of Immunomedics Inc. (NASDAQ:IMMU), Harout Semerjian is stepping down because of “unfortunate significant logistical obstacles presented by the COVID-19 pandemic,” according to the cancer company. Executive...
BioCentury | May 13, 2020
Product Development

Arvinas unveils first efficacy signal for targeted protein degradation, points to opportunity in resistant cancers

Arvinas’ top-line ASCO data provides the first evidence that targeted protein degraders can benefit patients, in particular those whose tumors have become resistant to standard therapies. Founded by targeted degradation pioneer Craig Crews in 2013,...
BioCentury | Apr 23, 2020
Product Development

April 22 Quick Takes: Accelerated approval for Immunomedics’ Trodelvy; plus BioNTech-Pfizer, AskBio, Astellas, Merck KGaA, oNKo-Gilead, Myovant, Afyx and Sangam

Immunomedics’ Trodelvy approved for TNBC FDA granted accelerated approval to Trodelvy sacituzumab govitecan from Immunomedics Inc. (NASDAQ:IMMU) for adult metastatic triple-negative breast cancer patients in the third-line setting. Immunomedics said continued approval of the TROP2-targeting...
BioCentury | Jan 25, 2020
Product Development

Radiotherapy blasts forward

High-wattage takeouts and commercial launches have revived interest in radiopharmaceuticals for cancer. The challenge for the new wave of candidates is to achieve enough differentiation to justify the logistical hurdles of manufacturing and delivering products...
BioCentury | Jan 16, 2020
Company News

Jan. 15 Company Quick Takes: Japan Tobacco gets rights to Dermavant therapy; plus Clovis, BMS, Recordati, BeiGene, Insilico-Pfizer, Novartis

Japan Tobacco gets Japanese rights to Dermavant’s dermatology therapy Japan Tobacco Inc. (TOKYO:2914) licensed from Dermavant Sciences exclusive rights to develop and commercialize tapinarof in Japan for dermatology indications including psoriasis and atopic dermatitis. The...
BioCentury | Dec 20, 2019
Product Development

Pharma spinouts: a snapshot of where and how pharmas spin out their assets

The handoff of innovation to academia is all but complete, with universities and other academic institutions accounting for the origin of about 75% of new companies formed in the last three years. But while pharma...
BioCentury | Nov 11, 2019
Emerging Company Profile

Mycovia tackling chronic infections with antifungal pipeline

Mycovia plans to bring a new generation of antifungals against CYP51 to market for difficult-to-treat indications, starting with chronic vaginal and nail infections. The company's lead product VT-1161 otesaconazole is in Phase III testing for...
BioCentury | Jun 19, 2019
Company News

June 18 Company Quick Takes: Sino-Akeso JV, plus Oxford Drug Design, Be The Match and more

CTTQ, Akeso form JV to develop PD-1 mAb The Chia Tai Tianqing Pharmaceutical Group Co. Ltd. (CTTQ) subsidiary of Sino Biopharmaceutical Ltd. (HKEX:1177) formed a 50/50 joint venture with Akeso Biopharma Inc. (Zhongshan, China) to...
Items per page:
1 - 10 of 702